Skip to main content
Fig. 3 | BMC Health Services Research

Fig. 3

From: Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region

Fig. 3

Analysis in scenario B. a) Pharmaceutical expenditure with related expected saving in proportion to the degree of penetration of the single-inhaler ICS/LAMA/LABA association on the market (with a penetration proportion of 30%, 50% and 100%, respectively). b) Reduction in expenditure for FF/UMEC/VI and for BDP/FOR/GB considering a penetration market share of 30%, and of 50%, respectively

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us